AI Prescription Program Sparks Debate in Utah

A new prescription program launched in Utah raises questions about artificial intelligence’s role in healthcare. The program allows residents to refill prescriptions online through an AI chatbot named Doctronic. This advancement offers convenience but challenges traditional medical regulations.

AI in Medicine

Proponents argue for updating laws that limit prescribing to licensed professionals to include AI tools. Dr. Eric Bressman from the University of Pennsylvania highlights the significant shift in granting medical-related responsibilities to non-human entities. Currently, AI lacks the authority to practice medicine under existing laws.

Doctors and experts do not oppose AI prescribing, but they emphasize that it should meet rigorous standards similar to those set for human doctors.

Regulatory Challenges

Doctronic’s launch was possible due to a “regulatory sandbox” in Utah, allowing relaxed laws for promising technologies. Human doctors review all AI-generated refill orders, though the program plans to automate refills soon.

Medical experts, including Dr. Alan Smith, express concerns about the lack of oversight by medical boards. The current structure divides regulation between state and federal authorities, complicating the integration of AI in healthcare.

State and Federal Roles

Doctronic treats AI as part of state-regulated medical practice, while the FDA oversees technologies impacting medical decisions. The FDA has yet to regulate AI chatbots comprehensively, leaving room for varied interpretations of legal responsibilities:

“Our goal is to provide healthcare access,” states Dr. Adam Oskowitz, Doctronic’s co-founder.

Other states such as Texas and Wyoming are relaxing rules for AI, while lawmakers in Idaho and Iowa propose legislation to formally license AI medical services.

Concerns from the Medical Community

Some in the medical field worry about automatic prescription renewals. Dr. Smith highlights dangers, citing that medical histories can change, making previous prescriptions inappropriate. Concerns led to the removal of several drugs from Doctronic’s refill list.

Despite these issues, Doctronic claims careful review procedures, often referring cases to human doctors when necessary. The American Medical Association also questions routine reliance on AI for prescription renewals.

FDA’s Approach

Dr. Bressman criticizes Utah for insufficient up-front data demands from Doctronic. He stresses the need for national guidelines, referencing historical medical standards that prioritized safety and training.

The FDA, while encouraging innovation, takes a cautious regulatory stance. This hands-off approach leaves states with different regulatory attitudes, potentially risking public trust in the long term.

Future Implications

Doctronic and similar companies may quickly expand across states with lenient regulations. However, they must weigh potential business benefits against the risk of undermining public confidence and inviting backlash.

For more information, the Associated Press Health and Science Department has related content.